SUBSCRIBE Blog with us: BLOGbiotech

GEN News Highlights

• Email
• Print
• Share
• More GEN News Highlights

Nov 27 2006, 1:52 PM EST

Mayne Acquires Remaining Rights to Hairy-Cell Leukemia Drug

GEN News Highlights

Mayne Pharma topped off its North American rights to SuperGen’s hairy-cell leukemia therapy by purchasing the remaining worldwide rights for $8 million. In August 2006, Mayne paid $34 million for the North American rights to Nipent® (pentostatin for injection).

SuperGen will receive approximately $3.75 million upfront. The balance includes $1.25 million to be paid depending on key events and $3 million over a five-year period on the anniversary of the closing date.

"This acquisition is in keeping with our strategy, announced last May, to acquire niche marketed or close-to-market proprietary products that strengthen our oncology focus across Europe,” remarks Mike Kotsanis, Mayne’s head of commercial operations for Europe, Middle-East, and Africa. Last year, Nipent reached European sales of almost $5 million.

• Email
• Print
• Share
• More GEN News Highlights

Comment on this News:

Name:
Title:
Comment:
	HELP US FIGHT SPAMMING ROBOTS by answering the following simple question. It will verify you as a legitimate user wishing to post a comment. Thank you for your cooperation.

CAREER CENTER

WEBINARS

PODCASTS

MOST POPULAR